With production picking up and demand still strong, Carvykti is catching up with Bristol Myers Squibb's first-to-market Abecma. In the second quarter, Abecma generated $132 million in sales, which marked a decline from $147 million in the first quarter. What's more, BMS expects its drug slide further in the third quarter because of a planned manufacturing maintenance period in June, BMS' CFO David Elkins said on the company's second-quarter earnings call.